Analysts Set Expectations for MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Marker Therapeutics in a research report issued on Wednesday, March 18th. Brookline Capital Markets analyst L. Cann forecasts that the company will earn ($0.19) per share for the quarter. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.64) EPS and FY2026 earnings at ($1.53) EPS.

Other equities analysts have also recently issued research reports about the stock. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, HC Wainwright began coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They set a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Marker Therapeutics Stock Up 1.5%

NASDAQ MRKR opened at $1.34 on Monday. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07. The firm has a market capitalization of $22.34 million, a P/E ratio of -1.58 and a beta of 1.42. The company has a 50-day moving average price of $1.59 and a 200-day moving average price of $1.30.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.17. The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%.

Institutional Investors Weigh In On Marker Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the third quarter valued at about $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics during the third quarter worth about $33,000. Jane Street Group LLC bought a new stake in Marker Therapeutics during the 2nd quarter valued at approximately $33,000. Boyer Financial Services Inc. bought a new stake in Marker Therapeutics during the 4th quarter valued at approximately $57,000. Finally, XTX Topco Ltd lifted its holdings in Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares in the last quarter. 22.39% of the stock is owned by institutional investors.

More Marker Therapeutics News

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $10.00 price target while publishing detailed quarterly and long‑term EPS model updates — a high-profile analyst backing that can attract buyers and liquidity. HC Wainwright research (via MarketBeat)
• Positive Sentiment: Brookline Cap M boosted its FY2026 EPS forecast for MRKR (revising the year loss from roughly ($2.74) to ($1.53)), signaling expectations for a smaller-than-previously-forecast cash burn or improved near‑term operating performance. Brookline Cap M note (via MarketBeat)
• Neutral Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 (Q1: ($0.33), Q2: ($0.36), Q3: ($0.38), Q4: ($0.30)) and a FY2030 EPS view of ($0.75) — useful modeling inputs but they still project ongoing losses for several years. HC Wainwright forecasts (via MarketBeat)
• Neutral Sentiment: Aggregator coverage summarized analyst Q2 forecasts for MRKR; these consensus/estimates pieces are informational and help set expectations ahead of upcoming reports. Equities Analysts Issue Forecasts for MRKR Q2 Earnings
• Negative Sentiment: Consensus still forecasts a full‑year loss (approx. ($0.65) EPS), and quarter-by-quarter models remain negative — continued losses and negative margins could limit valuation multiple expansion and keep the stock volatile. Consensus estimates (via MarketBeat)
• Negative Sentiment: Historical metrics show large negative margins and negative ROE (company remains unprofitable), meaning any deterioration in operating results or funding concerns would weigh on the share price. Company fundamentals (via MarketBeat)

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.